Evidence map›Paper›PMID 17068657›Full record

SynthesisOsteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA2007

Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes--a meta-analysis.

P Vestergaard

5 registry-linked trialsAbstract readMeta-AnalysisReview
PubMed Publisher
In one paragraph

Synthesis in Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 5 registered trials, which are not on this map. Cited by 867 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
867citing papers in PubMed, 7 pooled it
22.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02473809 phase4completedstarted 2015, after this paper: background citation

The Effect of Liraglutide on Bone Turnover, Bone Mass and Bone Cell Function

Ran2015Enrolled60Registered outcomes7Posted comparisons0ConditionsDiabetes Complications, OsteoporosisArmsliraglutide, Placebo
PMID 25074632PMID 21372151PMID 17925191PMID 18039776PMID 23023946PMID 7479679other papers from this trial
Open the trial in the graph
NCT01600924 active not recruitingnot on this mapstarted 2016, after this paper: background citation

Study on the Assessment of Determinants of Muscle and Bone Strength Abnormalities in Diabetes

TypeobservationalSponsorMetabolic Fitness Association, ItalyRan2016 to 2026Enrolled1,018ConditionsType 1 Diabetes, Type 2 Diabetes
NCT02421393 nacompletednot on this mapstarted 2018, after this paper: background citation

Study to Weigh the Effect of Exercise Training on BONE Quality and Strength (SWEET-BONE) in Type 2 Diabetes: an Exercise Intervention Program for Reducing the Risk of Fractures

TypeinterventionalSponsorMetabolic Fitness Association, ItalyRan2018 to 2024Enrolled200ConditionsType 2 DiabetesArmssupervised exercise training
NCT02435329 completednot on this mapstarted 2015, after this paper: background citation

Bone Metabolism and Endothelial Function in Patients With Type 2 Diabetes Mellitus and Charcot Foot - an Observational Comparative Study

TypeobservationalSponsorTameside General HospitalRan2015 to 2016Enrolled31ConditionsDiabetic Angiopathies, Bone Diseases, MetabolicArmsBaseline comparison of microcirculation and bone metabolism
NCT03457818 phase2terminatednot on this mapstarted 2018, after this paper: background citation

Therapy of the Skeletal Disease of Type 2 Diabetes With Denosumab

TypeinterventionalSponsorMishaela RubinRan2018 to 2020Enrolled8ConditionsDiabetes Mellitus, Type 2, OsteoporosisArmsDenosumab 60 mg/ml [Prolia], Placebo
3 · Its place in the literature

Who cites it

867 citing papers in PubMed, 7 syntheses or guidelines pooled it, 1,797 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Effects of Exogenous GIP and GLP-2 on Bone Turnover in Individuals With Type 2 Diabetes.The Journal of clinical endocrinology and metabolism · 2024
    Trial
  10. Trial
  11. Trial
  12. Trial
  13. Article
  14. Article
  15. Systemic glucocorticoid use increases fracture risk similarly in individuals with and without type 2 diabetes: a Danish nationwide cohort study.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2026
    Article
  16. Article
  17. Article
  18. Bone health in patients with cancer: a SEOM-SEIOMM consensus review of risk factors, assessment strategies, and management approaches.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Review
  19. Bone Fragility: Time to Address the Matrix.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2026
    Article
  20. Article

807 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

P VestergaardThe Osteoporosis Clinic, Aarhus Amtssygehus, Aarhus University Hospital, Tage Hansens Gade 2, 8000, Aarhus C, Denmark. p-vest@post4.tele.dk
Aarhus University Hospital · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introduction and hypothesisDiabetes affects bone metabolism. The hypothesis was that type 1 (T1D) and type 2 (T2D) affects BMD and fracture risk differently. MATERIAL AND

methodsPubmed, Embase, and Web of Science were searched using the terms "diabetes", "fracture", and "bone mineral".

resultsHip fracture risk was increased in T1D (RR = 6.94, 95% CI: 3.25-14.78, five studies) and T2D (1.38, 95% CI: 1.25-1.53, eight studies) compared to subjects without diabetes. The increase in relative hip fracture risk was significantly higher in T1D than in T2D. BMD Z-score was decreased in the spine (mean +/- SEM -0.22 +/- 0.01) and hip (-0.37 +/- 0.16) in T1D and increased in the spine (0.41 +/- 0.01) and hip (0.27 +/- 0.01) in T2D. A meta-regression showed that body mass index (BMI) was a major determinant for BMD in both the spine and hip. Glycated haemoglobin (HbA1C) was not linked to BMD. The increase in fracture risk was higher and BMD lower in patients with complications to diabetes.

conclusionsHip fracture risk is increased in both T1D and T2D, whereas BMD is increased in T2D and decreased in T1D. A common factor such as complications may explain the increase in fracture risk, whereas BMI may ameliorate the increase in fracture risk in T2D.

Indexed as

AdultAgedBody Mass IndexBone DensityDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2FemaleFractures, BoneGlycated HemoglobinHip FracturesHumansMaleMiddle AgedRisk FactorsGlycated Hemoglobin

Identifiers

PMID17068657
OpenAlexW2141260918

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.